{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T20:10:19Z","timestamp":1759176619300,"version":"3.44.0"},"reference-count":8,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100010643","name":"Cidara Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010643","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014923","name":"CymaBay Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017614","name":"Arrien Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jhep.2022.07.024","type":"journal-article","created":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T01:23:06Z","timestamp":1660440186000},"page":"1452-1453","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reply to: \u201cSeladelpar in patients with primary biliary cholangitis: Need for a closer look!\u201d"],"prefix":"10.1016","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3906-6811","authenticated-orcid":false,"given":"Christopher L.","family":"Bowlus","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5498-6037","authenticated-orcid":false,"given":"Cynthia","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon M.","family":"Hirschfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2022.07.024_bib1","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2022.02.033","article-title":"A\u00a0phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis","volume":"77","author":"Bowlus","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.024_bib2","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jhep.2022.04.039","article-title":"Seladelpar in patients with primary biliary cholangitis: need for a closer look!","volume":"77","author":"Mishra","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.024_bib3","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1097\/MCG.0b013e318261e659","article-title":"Primary biliary cirrhosis is more severe in overweight patients","volume":"47","author":"Hindi","year":"2013","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2022.07.024_bib4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/MCG.0b013e3181a84b8d","article-title":"Assessment of liver fibrosis and steatosis in PBC with FibroScan, MRI, MR-spectroscopy, and serum markers","volume":"44","author":"Friedrich-Rust","year":"2010","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2022.07.024_bib5","first-page":"1042A","article-title":"A\u00a052-week multi-center double-blind randomized phase 2 study of seladelpar, a potent and selective peroxisome proliferator-activated receptor delta (PPAR-delta) agonist, in patients with nonalcoholic steatohepatitis (NASH)","volume":"72","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"issue":"S1","key":"10.1016\/j.jhep.2022.07.024_bib6","first-page":"LO11","article-title":"ENHANCE: safety and efficacy of seladelpar in patients with primary biliary cholangitis\u2014a phase 3 international, randomized, placebo-controlled study","volume":"72","author":"Hirschfield","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.024_bib7","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/liv.15039","article-title":"Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis","volume":"42","author":"Kremer","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.07.024_bib8","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822029907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822029907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:47:13Z","timestamp":1759175233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822029907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":8,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0168827822029907"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.07.024","relation":{},"ISSN":["0168-8278"],"issn-type":[{"type":"print","value":"0168-8278"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to: \u201cSeladelpar in patients with primary biliary cholangitis: Need for a closer look!\u201d","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.07.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.04.039","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.02.033","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}